Algernon to acquire nobrainer imaging centers, inc. - plans to establish alzheimer's diagnostic and treatment medical clinics featuring new pet scan technology

Vancouver, british columbia, may 13, 2025 (globe newswire) -- algernon pharmaceuticals inc. (the “company” or “algernon”) (cse: agn) (frankfurt: agw0) (otcqb: agnpf), a canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of nobrainer imaging centers, inc. (“nic”) (the “transaction”). the transaction moves algernon into the alzheimer's disease (“ad”) diagnostic and treatment market, expanding on the company's neurological research programs, and provides algernon exclusive master franchise and licensing rights to open ad screening, diagnostic, and treatment centers across canada and in multiple u.s. markets.
PET Ratings Summary
PET Quant Ranking